Selective ligands for the dopamine 3 (D

1. A compound having a structural formula

wherein R 1 is methyl, ethyl, isopropyl, cyclopropyl,

wherein R 2 is

substituted with one, two halogen(s), OC 1-3 alkyl.

2. The compound of claim 1 wherein

3. A compound having a structural formula

4. A compound selected from the group consisting of

5. A method of treating a disease or condition wherein modulation of dopamine D 3 receptors provides a benefit comprising administering a compound of claim 1 to an individual having a disease selected from the group consisting of drug abuse, Parkinson's disease, restless leg syndrome, schizophrenia, and depression.

6. The method of claim 5 further comprising administering a therapeutically effective amount of a second therapeutic agent useful in the treatment of the disease or condition selected from the group consisting of drug abuse, Parkinson's disease, restless leg syndrome, schizophrenia, and depression.

7. The method of claim 5 wherein the compound of claim 1 and the second therapeutic agent are administered simultaneously.

8. The method of claim 6 wherein the compound of claim 1 and the second therapeutic agent are administered from a single composition.

9. The method of claim 6 wherein the compound of claim 1 and the second therapeutic agent are administered from separate compositions.

10. The method of claim 9 wherein the compound of claim 1 is administered prior to the second therapeutic agent.

11. The method of claim 9 wherein the compound of claim 1 is administered after the second therapeutic agent.

12. The method of claim 6 wherein the second therapeutic agent is selected from the group consisting of an antipsychotic agent, an antidepressant agent, a monoamine oxidase inhibitor, a 5-HT reuptake inhibitor, a serotonin-1 B antagonist, a serotonin-2A antagonist, a histamine-3 antagonist or agonist, and an antiparkinsonian agent.

13. The method of claim 12 wherein the second therapeutic agent is selected from the group consisting of clozapine, olanzapine, quetiapine, risperidone, ziprasidone, haloperidol, aripiprazole, a tricyclic antidepressant, amitriptyline, dothiepin, doxepin, trimipramine, butriptyline, clomipramine, desipramine, imipramine, iprindole, lofepramine, nortriptyline, protriptyline, isocarboxazid, phenelzine, tranylcyclopramine, fluvoxamine, sertraline, fluoxetine, paroxetine, elzasonan, eplivanserin, MDL-100907, cipralisant, ABT239, TISQ, GSK-189254A, a dopaminergic antiparkinsonian agent, and levodopa, alone or in combination with a peripheral decarboxylase inhibitor, benserazide, or carbidopa, or with a dopamine agonist, bromocriptine, lysuride, or pergolide, and mixtures thereof.

14. A kit comprising:

(a) a packaged composition comprising a compound of claim 1 ;

(b) optionally, a packaged composition comprising a second therapeutic agent useful in a treatment of a disease or condition wherein modulation of D 3 receptors provide a benefit;

(c) an insert providing instructions for a simultaneous or sequential administration (a), or (a) and (b), to treat a disease or condition wherein modulation of D 3 receptors provide a benefit in a human;

(d) a container for (a), (b), and (c),

wherein the disease or condition is selected from the group consisting of drug abuse, Parkinson's disease, restless leg syndrome, schizophrenia, and depression.

15. A composition comprising (a) compound of claim 1 , (b) a second therapeutic agent useful in the treatment of a disease or condition wherein modulation of D 3 receptors provide a benefit, and (c) an optional excipient and/or pharmaceutically acceptable carrier,

wherein the disease or condition is selected from the group consisting of drug abuse, Parkinson's disease, restless leg syndrome, schizophrenia, and depression.